Eli Lilly and Company Sees Unusually High Options Volume (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) was the recipient of some unusual options trading on Friday. Stock traders purchased 52,076 call options on the company. This is an increase of approximately 29% compared to the average daily volume of 40,231 call options.

Eli Lilly and Company Stock Up 7.0%

LLY opened at $1,206.51 on Friday. The firm has a market cap of $1.14 trillion, a P/E ratio of 42.86, a price-to-earnings-growth ratio of 1.32 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The business has a 50 day moving average price of $1,036.28 and a 200 day moving average price of $1,020.95. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,215.76.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter last year, the company posted $3.34 earnings per share. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts forecast that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia across all lines of therapy, which could expand Lilly’s oncology revenue opportunity in the EU. Article Title
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with new details on the Medicare GLP-1 Bridge program that could broaden access to Foundayo (orforglipron) and Zepbound for eligible Medicare Part D patients starting July 1. Article Title
• Positive Sentiment: Management’s expanded access push and continued clinical progress in obesity/diabetes are reinforcing the view that Lilly remains a leader in the weight-loss drug race, supporting bullish sentiment. Article Title
• Neutral Sentiment: Some recent coverage highlights Lilly’s strong pipeline and market leadership, but also notes valuation concerns and a less attractive entry point after the stock’s big run. Article Title
• Neutral Sentiment: News about Lilly launching its cancer drug Tanstrive in India adds another growth angle, but it appears to be a smaller near-term stock driver than the obesity and EU approval updates. Article Title

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Norges Bank bought a new position in shares of Eli Lilly and Company in the fourth quarter worth about $12,976,634,000. Capital Research Global Investors boosted its stake in Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after purchasing an additional 4,332,008 shares during the period. J. Stern & Co. LLP boosted its stake in Eli Lilly and Company by 46,191.3% during the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock valued at $4,047,245,000 after purchasing an additional 4,038,502 shares during the period. Cardano Risk Management B.V. grew its holdings in Eli Lilly and Company by 876.1% in the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock valued at $2,552,419,000 after buying an additional 2,131,734 shares during the last quarter. Finally, Fifth Third Bancorp grew its holdings in Eli Lilly and Company by 321.3% in the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after buying an additional 1,497,423 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on LLY shares. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 2nd. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 8th. Leerink Partners boosted their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research note on Thursday. Guggenheim restated a “buy” rating and issued a $1,183.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research report on Monday, June 22nd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,235.07.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.